Radiation therapy for prostate cancer in the new S3 guideline - Part 1: localized and locally advanced prostate cancer

被引:0
|
作者
Boehmer, D. [1 ]
Wenz, F. [2 ]
Martin, T. [3 ]
Sedlmayr, F. [4 ]
Hinkelbein, W. [5 ]
Wiegel, T. [6 ]
机构
[1] Charite, Klin Strahlentherapie, D-13353 Berlin, Germany
[2] Univ Klinikum Mannheim, Mannheim, Germany
[3] Praxisgemeinschaft Strahlentherapie & Radioonkol, Bremen, Germany
[4] Salzburger Landeskliniken, Klin Radiotherapie & Radioonkol, Salzburg, Austria
[5] Charite, Klin Radioonkol & Strahlentherapie, D-13353 Berlin, Germany
[6] Univ Ulm Klinikum, Klin Strahlentherapie & Radioonkol, Ulm, Germany
来源
UROLOGE | 2010年 / 49卷 / 02期
关键词
S3; guideline; Prostate cancer; Radiation therapy; Hormone therapy; INTENSITY-MODULATED RADIOTHERAPY; ANDROGEN SUPPRESSION; CONFORMAL RADIOTHERAPY; DOSE-ESCALATION; RADICAL PROSTATECTOMY; TRIAL; NEOADJUVANT; IRRADIATION; CARCINOMA; TOXICITY;
D O I
10.1007/s00120-010-2241-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Radiation therapy is a treatment option for curative management of localized and locally advanced prostate cancer. Depending on tumor stage and constellation of risk factors (PSA level, findings on digital rectal examination, and Gleason score), various forms of radiotherapy are applied. In addition to the sole use of external beam radiotherapy, brachytherapy with radioactive seeds is also employed as stand-alone treatment in patients with low risk factors and in early clinical stages. Increasing risk of recurrence requires more intensive therapies which can be accomplished by adding hormone deprivation therapy and/or intensifying radiation therapy (dose escalation). Combined approaches using brachytherapy and percutaneous radiotherapy are also initiated in these cases. If hormone ablation therapy is administered, this should occur over a course of 3-36 months as neoadjuvant, concommitant and/or adjuvant treatment, depending on the risk of recurrence.
引用
收藏
页码:211 / 215
页数:5
相关论文
共 50 条
  • [21] Guideline of guidelines: primary monotherapies for localised or locally advanced prostate cancer
    Lancee, Michelle
    Tikkinen, Kari A. O.
    de Reijke, Theo M.
    Kataja, Vesa V.
    Aben, Katja K. H.
    Vernooij, Robin W. M.
    BJU INTERNATIONAL, 2018, 122 (04) : 535 - 548
  • [22] Multimodal therapy of locally advanced prostate cancer
    Heidenreich, A.
    Boehmer, D.
    UROLOGE, 2016, 55 (03): : 333 - 344
  • [23] Role of radiation and androgen deprivation therapy for advanced prostate cancer
    Jani, Ashesh B.
    Rossi, Peter J.
    CURRENT PROBLEMS IN CANCER, 2015, 39 (01) : 41 - 47
  • [24] Primary radiation therapy for localized prostate cancer
    Eng, TY
    Thomas, CR
    Herman, TS
    UROLOGIC ONCOLOGY, 2002, 7 (06): : 239 - 257
  • [25] The Use of Androgen Deprivation Therapy in Combination With Radiation for Localized Prostate Cancer
    Anderson, Eric M.
    Mcbride, Sean M.
    FRONTIERS IN UROLOGY, 2022, 2
  • [26] Locally Advanced Prostate Cancer: Current Controversies and Optimisation Opportunities
    Sridharan, S.
    Dal Pra, A.
    Catton, C.
    Bristow, R. G.
    Warde, P.
    CLINICAL ONCOLOGY, 2013, 25 (08) : 499 - 505
  • [27] Management of prostate cancer. Part 2: Localized and locally advanced disease
    Sooriakumaran, Prasanna
    Khaksar, Sara Jane
    Shah, Jyoti
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (04) : 595 - 603
  • [28] DOES HORMONE THERAPY REDUCE DISEASE RECURRENCE IN PROSTATE CANCER PATIENTS RECEIVING DOSE-ESCALATED RADIATION THERAPY? AN ANALYSIS OF RADIATION THERAPY ONCOLOGY GROUP 94-06
    Valicenti, Richard K.
    Bae, Kwounghwa
    Michalski, Jeff
    Sandler, Howard
    Shipley, William
    Lin, Alex
    Cox, James
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (05): : 1323 - 1329
  • [29] The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer
    Numakura, Kazuyuki
    Kobayashi, Mizuki
    Muto, Yumina
    Sato, Hiromi
    Sekine, Yuya
    Sobu, Ryuta
    Aoyama, Yu
    Takahashi, Yoshiko
    Okada, Syuhei
    Sasagawa, Hajime
    Narita, Shintaro
    Kumagai, Satoshi
    Wada, Yuki
    Mori, Naoko
    Habuchi, Tomonori
    CURRENT ONCOLOGY, 2023, 30 (09) : 8092 - 8110
  • [30] Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer
    Iwamoto, Hiroaki
    Izumi, Kouji
    Makino, Tomoyuki
    Mizokami, Atsushi
    CANCERS, 2022, 14 (07)